396 filings
Page 3 of 20
8-K
92b9 bj0hir8
11 Aug 22
Acasti Pharma Reports First Quarter 2023 Operational Results
7:05am
8-K
fi8cufj
29 Jul 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:01pm
424B3
zlidh
23 Jun 22
Prospectus supplement
4:41pm
8-K
zlghaxjbe5ad h40
21 Jun 22
Results of Operations and Financial Condition
8:10am
8-K
skg08a663lb
18 May 22
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, with Intravenous GTX-104 Meeting All Endpoints
7:37am
8-K
shgt9veuf
25 Mar 22
Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors
7:36am
8-K
tq5dbd5 0yl0
14 Feb 22
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022
7:10am
8-K
02ve 6hely22m3c
2 Dec 21
Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104
7:17am
8-K
eav93dnww3kldxpe
15 Nov 21
Acasti Pharma Announces Annual Stock Option Grants
12:00am
424B5
wxktbtrf
10 Nov 21
Prospectus supplement for primary offering
7:23am
8-K
edqrkgus
10 Nov 21
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022
7:09am
8-K/A
b6j75sfg10pgsdfl49xg
5 Nov 21
Financial Statements and Exhibits
4:07pm
8-K
eonrx mpagtks
22 Sep 21
Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards
8:30am
8-K
fa84y8h6
9 Sep 21
Amendments to Articles of Incorporation or Bylaws
4:19pm